• Zoledronic Acid: From Cell Death to Bone Biology

  2026-09-24

  Explore how Zoledronic Acid, a nitrogen-containing bisphosphonate, can be studied across cancer-cell and bone-disease models. This article focuses on experimental design, endpoint interpretation, and a carefully bounded lesson from new mechanistic research in immunology.

• Brefeldin A: From Trafficking Blockade to ER Stress

  2026-09-23

  Explore how Brefeldin A connects ER-to-Golgi trafficking disruption with protein quality control and cancer-cell stress responses—and how translational researchers can design experiments that distinguish mechanism from outcome.

• IRG1–Itaconic Acid Restraint of TBK1 Signaling

  2026-09-23

  A 2025 Cell Reports study identifies an IRG1–itaconic acid feedback mechanism that restrains excessive TBK1-dependent type I interferon production. The work links immunometabolism to TBK1 alkylation at Cys605, impaired dimerization, and the development of itaconic acid-derived inhibitors ITA-5 and ITA-9 for hyperinflammatory settings.

• Ruxolitinib in Anaplastic Thyroid Cancer

  2026-09-22

  The reference study identifies a mechanistic link between JAK1/2–STAT3 signaling, DRP1-dependent mitochondrial fission, apoptosis, and GSDME-mediated pyroptosis in anaplastic thyroid carcinoma. Its findings position ruxolitinib as a useful preclinical probe for studying transcriptional control of mitochondrial dynamics and cancer-cell death, while remaining distinct from clinical evidence.

• MK-8745: A Practical Aurora A Inhibitor Workflow

  2026-09-22

  Build a mechanism-first workflow around MK-8745 to connect Aurora A inhibition with mitotic arrest, apoptosis, lymphoma biology, and xenograft response. This guide separates target validation from phenotype interpretation and provides practical formulation, assay, and troubleshooting decisions.

• K⁺ Channel Blockade and Renal Flow in Sepsis

  2026-09-21

  The reference study used complementary perfused-kidney and in vivo experiments to show that potassium-channel blockade can worsen renal hypoperfusion during vasoactive treatment in septic rats. Its central contribution is to distinguish baseline renal blood flow from pressor-agent responses, highlighting why channel subtype and sepsis timing matter in vascular biology research.

• Isochlorogenic Acid A Hydrogel for Wound Repair

  2026-09-21

  A 2026 Gels study addressed the poor aqueous compatibility and limited stability of Isochlorogenic acid A by co-assembling it with Fe(III) into nanoparticles and embedding them in an amylopectin/carboxymethyl chitosan hydrogel. The resulting dressing combined antibacterial activity, favorable mechanical and self-healing properties, enhanced cell migration, inflammatory-marker modulation, and improved wound closure in preclinical testing.

• ARCA EGFP mRNA for Delivery-System QC

  2026-09-20

  ARCA EGFP mRNA provides a direct fluorescence readout for separating delivery performance from mammalian cell gene expression. This article develops a systems-level framework for using enhanced green fluorescent protein mRNA to troubleshoot lipid nanoparticle and transfection workflows.

• WDR36, Glycolysis, and Human Trophectoderm Fate

  2026-09-19

  This study uses mouse embryos and human stem cell-derived blastoids to identify WDR36 as a regulator of trophectoderm differentiation linked to glycolytic metabolism. Transcriptomic, metabolomic, and protein-interaction evidence supports a WDR36–LDHA mechanism during late blastoid formation, while also highlighting the limits of translating blastoid findings directly to human embryos.

• Forsythoside E: A Causal Assay Framework

  2026-09-18

  Forsythoside E is a pyruvate kinase M2 (PKM2) inhibitor with a distinctive immunometabolic mechanism. This guide connects structural provenance, target engagement, macrophage metabolism, and sepsis-induced liver injury research into a rigorous assay strategy.

• Idoxuridine: From Mechanism to Assay Design

  2026-09-18

  Idoxuridine, also known as 5-iodo-2'-deoxyuridine, is a powerful research tool for examining viral DNA synthesis inhibition. This guide connects its nucleoside mechanism and physicochemical handling to rigorous assay design, while extracting transferable lessons from human-neuron pharmacology research.

• BRCAness and Olaparib in Pleural Mesothelioma

  2026-09-17

  Borchert et al. linked homologous recombination repair gene-expression patterns with olaparib sensitivity in malignant pleural mesothelioma, highlighting BAP1-associated vulnerability and potential cisplatin combinations. The study provides a translational framework for biomarker-guided treatment research while emphasizing that its conclusions remain primarily in vitro and require clinical validation.

• MG-132 as a Probe of Stress-Adaptive Ubiquitination

  2026-09-17

  MG-132 is more than a proteasome inhibitor: it can help map how ubiquitin-chain dynamics, proteostasis, oxidative stress, and apoptosis interact. This article translates new UFD1s findings into a control-driven framework for interpreting MG-132 experiments in cancer research and cell biology.

• AO/PI Double Staining Kit: Practical Workflow

  2026-09-16

  The AO/PI Double Staining Kit provides a rapid fluorescent readout for separating viable, apoptotic-like, and membrane-compromised cells in a single sample. It is suitable for screening cell viability, apoptosis detection, and necrosis detection, but should not be used as a standalone molecular confirmation of cell-death pathways.

• Rosiglitazone in PPARγ Variant Rescue Assays

  2026-09-16

  Rosiglitazone, also known as Brl-49653, provides a practical ligand-rescue tool for connecting PPARγ transcriptional defects with adipocyte metabolism. This workflow extends routine adipogenesis assays by combining reporter activity, receptor stability, mitochondrial function, and insulin-sensitivity endpoints.

8585 records 1/573 page Next 12345 下5页 Last page